UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)

被引：0
|
作者：
Gullick, G. [1 ]
Owen, C. [2 ]
Cook, S. [3 ]
Helbrow, J. [4 ]
Squires, R. [1 ]
Reed, H. M. [1 ]
Park, S.
Weir, E. [5 ]
Aquilina, F. [5 ]
Webber, N. [6 ]
Nye, E. [6 ]
Atkinson, C. [3 ]
Blair, C. [1 ]
Halstead, A. [1 ]
Daniels, E. [4 ]
Alves, A. [1 ]
Chew, S. [5 ]
Thomas, W. [4 ]
Spensley, S. [3 ]
Robinson, T. [2 ]
机构：
[1] Bristol Canc Inst, Med Oncol Dept, Bristol, England
[2] Univ Bristol, Fac Hlth Sci, Bristol Med Sch, Bristol, England
[3] Taunton & Somerset NHS Fdn Trust, Oncol Dept, Musgrove Pk Hosp, Taunton, England
[4] Gloucestershire Hosp NHS Fdn Trust, Oncol Dept, Gloucestershire Oncol Ctr, Cheltenham Gen Hosp, Cheltenham, England
[5] NHS Royal Devon Univ Healthcare, Oncol Dept, Royal Devon & Exeter Hosp Wonford, Exeter, England
[6] Royal United Hosp Bath NHS Fdn trust, Oncol Dept, Bath, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
422P
引用
收藏
页码：S360 / S360
页数：1
相关论文
共 50 条
  • [21] Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
    De Angelis, Claudia
    Ignatiadis, Michail
    Piccart-Gebhart, Martine
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (21)
  • [22] Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis
    Gerratana, Lorenzo
    Davis, Andrew A.
    Velimirovic, Marko
    Reduzzi, Carolina
    Clifton, Katherine
    Bucheit, Leslie
    Hensing, Whitney L.
    Shah, Ami N.
    Pivetta, Tania
    Dai, Charles S.
    D'Amico, Paolo
    Wehbe, Firas
    Medford, Arielle
    Wander, Seth A.
    Gradishar, William J.
    Behdad, Amir
    Ma, Cynthia X.
    Puglisi, Fabio
    Bardia, Aditya
    Cristofanilli, Massimo
    JCO PRECISION ONCOLOGY, 2023, 7
  • [23] Predictors of non-receipt of first-line CDK 4/6 inhibitors (CDK4/6i) among patients with metastatic breast cancer (MBC).
    Lee, Kimberley T.
    Chiao, Elaine
    Lim, David
    Mouslim, Morgane
    Wang, Chenguang
    Mangini, Neha
    Stearns, Vered
    Smith, Karen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India
    Majumdar, Saroj Kumar Das
    Barik, Sandip Kumar
    Pattanaik, Ashutosh
    Das, Deepak Kumar
    Parida, Kumar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [25] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [26] Real-world (RW) utilization and patient outcomes across three CDK4/6 inhibitors in metastatic breast cancer (mBC)
    Weipert, Caroline
    Wander, Seth
    Davis, Andrew
    Bucheit, Leslie
    Saha, Jayati
    Liao, Jiemin
    Zhang, Nicole
    Stover, Daniel
    Bardia, Aditya
    Cristofanilli, Massimo
    CANCER RESEARCH, 2024, 84 (09)
  • [27] Concurrent Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors with Palliative Radiotherapy for Metastatic Breast Cancer Patients: A Review of Toxicity
    Sonmez, Ozlem
    Tezcanli, Evrim
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2021, 36 (04): : 538 - 542
  • [28] Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging
    Huang, Chun-Han
    Khan, Palwasha
    Xu, Sulan
    Cohen, Jules
    Georgakis, Georgios V.
    Turkman, Nashaat
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (13)
  • [29] Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
    Miron, Andreea-Iuliana
    Anghel, Alexandra-Valentina
    Barnonschi, Andrei-Alexandru
    Mitre, Ruxandra
    Liscu, Horia-Dan
    Gainariu, Estera
    Patru, Raluca
    Coniac, Simona
    DIAGNOSTICS, 2023, 13 (11)
  • [30] Real-world benefit of CDK4/6 inhibitor and endocrine therapy combination in metastatic breast cancer and correlation with neutropenia
    Jenneman, Dakota
    Zhong, Xiaojun
    Ma, Junjie
    Sun, Weihong
    Han, Heather
    Soliman, Hatem
    Loftus, Loretta
    Costa, Ricardo
    Armaghani, Avan
    Soyano, Aixa
    Czerniecki, Brian
    Lee, M. Catherine
    Kiluk, John
    Khakpour, Nazanin
    Hoover, Susan
    Laronga, Christine
    Khong, Hung T.
    CANCER RESEARCH, 2020, 80 (04)
12345